Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma
Prostate carcinoma may develop into metastatic castration-resistant prostate carcinoma (mCRPC) after endocrine therapy. Exosomal microRNAs play an important role in the regulation of tumor microenvironment. Our study aimed to investigate the effect of exosomal miR-26a on tumor phenotype of prostate...
Saved in:
| Published in | Biomedicine & pharmacotherapy Vol. 117; p. 109109 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
France
Elsevier Masson SAS
01.09.2019
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0753-3322 1950-6007 1950-6007 |
| DOI | 10.1016/j.biopha.2019.109109 |
Cover
Loading…
| Abstract | Prostate carcinoma may develop into metastatic castration-resistant prostate carcinoma (mCRPC) after endocrine therapy. Exosomal microRNAs play an important role in the regulation of tumor microenvironment. Our study aimed to investigate the effect of exosomal miR-26a on tumor phenotype of prostate carcinoma. Low-grade prostate carcinoma cell line (LNCAP) and mCRPC cell line (PC-3) were treated as experimental subjects according to their miR-26a expressions. Wound healing, transwell and colony-forming unit assays were performed after miR-26a mimic/inhibitor transfection. Then, exosomes were isolated from LNCAP and PC-3 cells, and the levels of exosomal miR-26a were determined. After co-culture of LNCAP (PC-3) cells with PC-3 (LNCAP) exosomes, changes in malignant behaviors were measured. Moreover, LNCAP/PC-3 exosomes were injected into xenograft tumor mice to determine effects of the exosomes on tumorigenicity of LNCAP and PC-3 cells. MiR-26a showed a potently inhibitory effect on cell proliferation, migration and invasion of LNCAP and PC-3 cells. LNCAP exosomes had a higher miR-26a level, compared with PC-3 exosomes. Overexpression of miR-26a attenuated the enhanced malignant behavior of LNCAP cells induced by PC-3 exosomes, and miR-26a inhibition could reverse the inhibitory effects of LNCAP exosomes on PC-3 cells. Exosomal miR-26a could significantly alter the expressions of epithelial-mesenchymal transition (EMT)-related factors. Moreover, LNCAP exosomes suppressed the tumorigenicity of PC-3 cells, while PC-3 exosomes could promote the tumorigenicity of LNCAP cells. Our data suggest that exosomal miR-26a derived from prostate carcinoma cells had a suppressive effect on the metastasis and tumor growth of prostate carcinoma. |
|---|---|
| AbstractList | Prostate carcinoma may develop into metastatic castration-resistant prostate carcinoma (mCRPC) after endocrine therapy. Exosomal microRNAs play an important role in the regulation of tumor microenvironment. Our study aimed to investigate the effect of exosomal miR-26a on tumor phenotype of prostate carcinoma. Low-grade prostate carcinoma cell line (LNCAP) and mCRPC cell line (PC-3) were treated as experimental subjects according to their miR-26a expressions. Wound healing, transwell and colony-forming unit assays were performed after miR-26a mimic/inhibitor transfection. Then, exosomes were isolated from LNCAP and PC-3 cells, and the levels of exosomal miR-26a were determined. After co-culture of LNCAP (PC-3) cells with PC-3 (LNCAP) exosomes, changes in malignant behaviors were measured. Moreover, LNCAP/PC-3 exosomes were injected into xenograft tumor mice to determine effects of the exosomes on tumorigenicity of LNCAP and PC-3 cells. MiR-26a showed a potently inhibitory effect on cell proliferation, migration and invasion of LNCAP and PC-3 cells. LNCAP exosomes had a higher miR-26a level, compared with PC-3 exosomes. Overexpression of miR-26a attenuated the enhanced malignant behavior of LNCAP cells induced by PC-3 exosomes, and miR-26a inhibition could reverse the inhibitory effects of LNCAP exosomes on PC-3 cells. Exosomal miR-26a could significantly alter the expressions of epithelial-mesenchymal transition (EMT)-related factors. Moreover, LNCAP exosomes suppressed the tumorigenicity of PC-3 cells, while PC-3 exosomes could promote the tumorigenicity of LNCAP cells. Our data suggest that exosomal miR-26a derived from prostate carcinoma cells had a suppressive effect on the metastasis and tumor growth of prostate carcinoma.Prostate carcinoma may develop into metastatic castration-resistant prostate carcinoma (mCRPC) after endocrine therapy. Exosomal microRNAs play an important role in the regulation of tumor microenvironment. Our study aimed to investigate the effect of exosomal miR-26a on tumor phenotype of prostate carcinoma. Low-grade prostate carcinoma cell line (LNCAP) and mCRPC cell line (PC-3) were treated as experimental subjects according to their miR-26a expressions. Wound healing, transwell and colony-forming unit assays were performed after miR-26a mimic/inhibitor transfection. Then, exosomes were isolated from LNCAP and PC-3 cells, and the levels of exosomal miR-26a were determined. After co-culture of LNCAP (PC-3) cells with PC-3 (LNCAP) exosomes, changes in malignant behaviors were measured. Moreover, LNCAP/PC-3 exosomes were injected into xenograft tumor mice to determine effects of the exosomes on tumorigenicity of LNCAP and PC-3 cells. MiR-26a showed a potently inhibitory effect on cell proliferation, migration and invasion of LNCAP and PC-3 cells. LNCAP exosomes had a higher miR-26a level, compared with PC-3 exosomes. Overexpression of miR-26a attenuated the enhanced malignant behavior of LNCAP cells induced by PC-3 exosomes, and miR-26a inhibition could reverse the inhibitory effects of LNCAP exosomes on PC-3 cells. Exosomal miR-26a could significantly alter the expressions of epithelial-mesenchymal transition (EMT)-related factors. Moreover, LNCAP exosomes suppressed the tumorigenicity of PC-3 cells, while PC-3 exosomes could promote the tumorigenicity of LNCAP cells. Our data suggest that exosomal miR-26a derived from prostate carcinoma cells had a suppressive effect on the metastasis and tumor growth of prostate carcinoma. Prostate carcinoma may develop into metastatic castration-resistant prostate carcinoma (mCRPC) after endocrine therapy. Exosomal microRNAs play an important role in the regulation of tumor microenvironment. Our study aimed to investigate the effect of exosomal miR-26a on tumor phenotype of prostate carcinoma. Low-grade prostate carcinoma cell line (LNCAP) and mCRPC cell line (PC-3) were treated as experimental subjects according to their miR-26a expressions. Wound healing, transwell and colony-forming unit assays were performed after miR-26a mimic/inhibitor transfection. Then, exosomes were isolated from LNCAP and PC-3 cells, and the levels of exosomal miR-26a were determined. After co-culture of LNCAP (PC-3) cells with PC-3 (LNCAP) exosomes, changes in malignant behaviors were measured. Moreover, LNCAP/PC-3 exosomes were injected into xenograft tumor mice to determine effects of the exosomes on tumorigenicity of LNCAP and PC-3 cells. MiR-26a showed a potently inhibitory effect on cell proliferation, migration and invasion of LNCAP and PC-3 cells. LNCAP exosomes had a higher miR-26a level, compared with PC-3 exosomes. Overexpression of miR-26a attenuated the enhanced malignant behavior of LNCAP cells induced by PC-3 exosomes, and miR-26a inhibition could reverse the inhibitory effects of LNCAP exosomes on PC-3 cells. Exosomal miR-26a could significantly alter the expressions of epithelial-mesenchymal transition (EMT)-related factors. Moreover, LNCAP exosomes suppressed the tumorigenicity of PC-3 cells, while PC-3 exosomes could promote the tumorigenicity of LNCAP cells. Our data suggest that exosomal miR-26a derived from prostate carcinoma cells had a suppressive effect on the metastasis and tumor growth of prostate carcinoma. |
| ArticleNumber | 109109 |
| Author | Yu, Guoqiang Li, Wensheng Zhu, Zhiyi Wang, Xiangwei Wang, Xiaobin Jia, Zhaohui Wang, Xi |
| Author_xml | – sequence: 1 givenname: Xiaobin surname: Wang fullname: Wang, Xiaobin organization: Department of Urology Surgery, Shenzhen University General Hospital (Shenzhen University Medical Academy), China – sequence: 2 givenname: Xi surname: Wang fullname: Wang, Xi organization: Department of Plastic Surgery, The First Affiliated Hospital, and Clinical Medicine College of Henan University of Science and Technology, China – sequence: 3 givenname: Zhiyi surname: Zhu fullname: Zhu, Zhiyi organization: Department of Urology Surgery, The First Affiliated Hospital, and Clinical Medicine College of Henan University of Science and Technology, China – sequence: 4 givenname: Wensheng surname: Li fullname: Li, Wensheng organization: Department of Urology Surgery, The First Affiliated Hospital, and Clinical Medicine College of Henan University of Science and Technology, China – sequence: 5 givenname: Guoqiang surname: Yu fullname: Yu, Guoqiang organization: Department of Urology Surgery, The First Affiliated Hospital, and Clinical Medicine College of Henan University of Science and Technology, China – sequence: 6 givenname: Zhaohui surname: Jia fullname: Jia, Zhaohui organization: Department of Urology Surgery, The First Affiliated Hospital, and Clinical Medicine College of Henan University of Science and Technology, China – sequence: 7 givenname: Xiangwei surname: Wang fullname: Wang, Xiangwei email: waxw_xiww@163.com organization: Department of Urology Surgery, Shenzhen University General Hospital (Shenzhen University Medical Academy), China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31229922$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkV1rFDEYhYO02G3rPxDJpTez5mMmyYgIpfgFrUrR65DJvHGzzky2Sabaf2-WaW_qxUIg8HKek7znnKKjKUyA0EtK1pRQ8Wa77nzYbcyaEdqWUVvOM7SibUMqQYg8QisiG15xztgJOk1pSwhpBFfP0QmnjLUtYys0f48hZZMBWxOtn8JosIVhqHqI_g56DH9DKsMBX3sbw83Xi4oJg8fQz0OhEs4bwCNkU0yST9hMPc7zGCL-FcOfvMHB4d1_T5yjY2eGBC8e7jP08-OHH5efq6tvn75cXlxVthY0V4o1QA1hvLZcSuG6ToDqVc3qVhLqFGmU4Uo5EJTLTja9kUQ67lTDW-vA8TP0evEtX7idIWU9-rRfz0wQ5qQZqwWrFeOqSF89SOduhF7voh9NvNePURXB20VQYkgpgtPWl618mHI0ftCU6H0vequXXvS-F730UuD6CfzofwB7v2BQQrrzEHWyHiYLvY9gs-6DP2Tw7omBHfzkrRl-w_1h_B-WEb3M |
| CitedBy_id | crossref_primary_10_1039_D0MA00455C crossref_primary_10_1186_s40364_022_00398_w crossref_primary_10_3390_vaccines10020276 crossref_primary_10_3389_fcell_2022_752818 crossref_primary_10_1016_j_ncrna_2024_07_003 crossref_primary_10_3389_fbioe_2024_1444201 crossref_primary_10_1038_s41392_021_00779_x crossref_primary_10_3390_app12157390 crossref_primary_10_3390_pharmaceutics16111347 crossref_primary_10_1007_s12038_021_00190_2 crossref_primary_10_3390_biology12050710 crossref_primary_10_3389_fcell_2021_679527 crossref_primary_10_3389_fcell_2023_1192937 crossref_primary_10_3390_cancers12113455 crossref_primary_10_1007_s13258_021_01177_x crossref_primary_10_1177_15330338231198348 crossref_primary_10_1039_D4TB02480J crossref_primary_10_3389_fruro_2022_843597 crossref_primary_10_32948_auo_2023_03_14 crossref_primary_10_3390_ijms22042100 crossref_primary_10_3389_fonc_2022_1118101 crossref_primary_10_3390_cells9040861 crossref_primary_10_1016_j_chemosphere_2022_136560 crossref_primary_10_1002_biof_2036 crossref_primary_10_1016_j_cellsig_2021_110126 |
| Cites_doi | 10.1210/me.2010-0469 10.1016/j.juro.2013.05.005 10.1016/j.canlet.2015.12.022 10.1007/s12015-017-9762-0 10.1093/annonc/mdx283 10.1182/blood.V98.10.3143 10.18632/oncotarget.8517 10.18632/oncotarget.7052 10.1021/acs.molpharmaceut.9b00104 10.1200/JCO.2007.12.4008 10.1016/j.gdata.2016.05.010 10.1083/jcb.41.1.59 10.1016/j.molcel.2010.06.010 10.1002/jcb.27850 10.1186/s12943-017-0600-4 10.1016/j.ctrv.2017.04.008 10.1038/jhg.2016.68 10.3892/or.2016.4660 10.1159/000493218 10.1056/NEJMoa041318 10.1186/s12967-016-1056-9 10.3892/ol.2016.5070 10.1016/j.ejphar.2017.07.023 10.1158/0008-5472.CAN-15-1625 10.1007/s13277-014-2206-4 10.1038/aja.2013.37 10.1016/j.ccell.2014.09.005 10.3892/ijo.2015.3043 10.1007/s10529-006-9127-2 10.1136/bmj.g1502 10.1038/sj.leu.2404132 10.1007/s00432-018-2786-2 10.1146/annurev-cellbio-101512-122326 10.1007/s11010-017-3012-2 10.1159/000485780 10.1007/s13277-016-5158-z 10.1038/sj.leu.2404296 10.1080/03008880510030914 10.1074/jbc.M113.489302 10.1016/j.canlet.2013.02.019 10.1002/pros.22987 10.1007/s00432-016-2222-4 |
| ContentType | Journal Article |
| Copyright | 2019 The Authors Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved. |
| Copyright_xml | – notice: 2019 The Authors – notice: Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.biopha.2019.109109 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1950-6007 |
| ExternalDocumentID | 31229922 10_1016_j_biopha_2019_109109 S0753332219318177 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 23N 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABMAC ABMZM ABWVN ABXDB ABZDS ACDAQ ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AI. AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W KOM M34 M41 MO0 N9A O-L O9- OAUVE OD~ OGGZJ OK1 OO0 OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SDF SDG SDP SEM SES SEW SPT SSH SSP SSZ T5K VH1 WUQ Z5R ~02 ~G- 0SF 6I. AACTN AAFTH AAIAV AATCM ABLVK ABYKQ AFCTW AFKWA AFPKN AJBFU AJOXV AMFUW EFLBG GROUPED_DOAJ LCYCR NCXOZ RIG AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 AGRNS |
| ID | FETCH-LOGICAL-c461t-825e1a0234c3776fbb6e8d84249701f8058a388fe6137b75da707f3f8539cfef3 |
| IEDL.DBID | .~1 |
| ISSN | 0753-3322 1950-6007 |
| IngestDate | Tue Aug 05 10:00:29 EDT 2025 Wed Feb 19 02:31:08 EST 2025 Wed Sep 03 16:44:28 EDT 2025 Thu Apr 24 22:56:40 EDT 2025 Fri Feb 23 02:40:22 EST 2024 Tue Aug 26 16:34:45 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Prostate carcinoma microRNA-26a Exosomes Castration-resistant prostate carcinoma |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c461t-825e1a0234c3776fbb6e8d84249701f8058a388fe6137b75da707f3f8539cfef3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0753332219318177 |
| PMID | 31229922 |
| PQID | 2246248238 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2246248238 pubmed_primary_31229922 crossref_citationtrail_10_1016_j_biopha_2019_109109 crossref_primary_10_1016_j_biopha_2019_109109 elsevier_sciencedirect_doi_10_1016_j_biopha_2019_109109 elsevier_clinicalkey_doi_10_1016_j_biopha_2019_109109 |
| PublicationCentury | 2000 |
| PublicationDate | September 2019 2019-09-00 2019-Sep 20190901 |
| PublicationDateYYYYMMDD | 2019-09-01 |
| PublicationDate_xml | – month: 09 year: 2019 text: September 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | Biomedicine & pharmacotherapy |
| PublicationTitleAlternate | Biomed Pharmacother |
| PublicationYear | 2019 |
| Publisher | Elsevier Masson SAS |
| Publisher_xml | – name: Elsevier Masson SAS |
| References | Ahadi, Khoury, Losseva, Tran (bib0205) 2016; 9 Kato, Kurozumi, Goto, Matsushita, Okato, Nishikawa, Fukumoto, Koshizuka, Ichikawa, Seki (bib0180) 2017; 62 Barrera-Ramirez, Lavoie, Maganti, Stanford, Ito, Sabloff, Brand, Rosu-Myles, Le, Allan (bib0195) 2017; 13 Pullan, Confeld, Orborn, Kim, Sarkar, Mallik (bib0235) 2019; 16 Guo, Zheng, Xu, Xu, Chen, Wen (bib0190) 2016; 37 Li, Ren, Tang, Yu (bib0125) 2017; 44 Wang, Guan, Zhang, Ge, Zhang, Li, Wang, Liu, Ning, Deng, Zhang, Jiang, Ba, Huang (bib0130) 2018; 49 Wang, Chen, Liu, Tian (bib0200) 2016; 14 Ratajczak, Miekus, Kucia, Zhang, Reca, Dvorak, Ratajczak (bib0120) 2006; 20 Zhang, Liu, Chen, Li, Li, Bian, Sun, Lu, Yin, Cai, Sun, Wang, Ba, Wang, Wang, Yang, Liu, Xu, Yan, Zhang, Zen, Zhang (bib0225) 2010; 39 Cookson, Roth, Dahm, Engstrom, Freedland, Hussain, Lin, Lowrance, Murad, Oh, Penson, Kibel (bib0050) 2013; 190 Janowska-Wieczorek, Majka, Kijowski, Baj-Krzyworzeka, Reca, Turner, Ratajczak, Emerson, Kowalska, Ratajczak (bib0110) 2001; 98 Erdmann, Kaulke, Rieger, Salomo, Wirth, Fuessel (bib0140) 2016; 142 Ren, Chen, Sun (bib0020) 2013; 15 Anderson (bib0085) 1969; 41 Xie, Liu, Dai, Lu, Dong, Huang (bib0070) 2019; 145 Chen, Clegg, Scher (bib0025) 2009; 10 Kato, Goto, Matsushita, Kurozumi, Fukumoto, Nishikawa, Sakamoto, Enokida, Nakagawa, Ichikawa, Seki (bib0185) 2015; 47 Dai, Gu, Chen, Marriott (bib0230) 2016; 7 Siegel, Miller, Jemal (bib0005) 2015; 65 Fleige, Walf, Huch, Prgomet, Sehm, Pfaffl (bib0150) 2006; 28 Galletti, Leach, Lam, Tagawa (bib0040) 2017; 57 Uchiyama, Tanaka, Kawamoto (bib0145) 2017; 812 Hosseini-Beheshti, Choi, Weiswald, Kharmate, Ghaffari, Roshan-Moniri, Hassona, Chan, Chin, Tai, Rennie, Fazli, Tomlinson Guns (bib0115) 2016; 7 Kavya, Kumar, Patil, Hegde, Kiran Kumar, Nagesh, Babu, Ramesh, Chidananda Sharma (bib0160) 2017; 433 Srigley, Amin, Boccon-Gibod, Egevad, Epstein, Humphrey, Mikuz, Newling, Nilsson, Sakr, Wheeler, Montironi (bib0010) 2005 Berthold, Pond, Soban, de Wit, Eisenberger, Tannock (bib0055) 2008; 26 Petrylak, Tangen, Hussain, Lara, Jones, Taplin, Burch, Berry, Moinpour, Kohli, Benson, Small, Raghavan, Crawford (bib0060) 2004; 351 Liu, Liu, Guo, Liang, Tian, Lu, Zhao, Sun, Zhao, Zhang, Dong (bib0065) 2015; 75 Yuan, Jiang, Sun, Chen (bib0075) 2016; 35 Zhang, Liang, Huang (bib0015) 2016; 12 Rathkopf, Smith, Ryan, Berry, Shore, Liu, Higano, Alumkal, Hauke, Tutrone, Saleh, Chow Maneval, Thomas, Ricci, Yu, de Boer, Trinh, Kheoh, Bandekar, Scher, Antonarakis (bib0045) 2017; 28 Ratajczak, Wysoczynski, Hayek, Janowska-Wieczorek, Ratajczak (bib0100) 2006; 20 Li, Zhang, Liu, Dai, Li, Cai, Yin, Wang, Xue, Wang, Li, Hou, Jiang, Zhang, Zen, Chen, Zhang (bib0210) 2013; 288 Zhao, Ye, Xiao, Lian, Feng, Li, Li (bib0135) 2014; 35 Yang, Wu (bib0170) 2017; 21 Prasetyanti, Medema (bib0155) 2017; 16 Kaighn, Narayan, Ohnuki, Lechner, Jones (bib0165) 1979; 17 Li, Li, Wang, Wang, Jiang, Wang, Li, Chen, Liu, Li, Zhu (bib0215) 2016; 76 Sooriakumaran, Nyberg, Akre, Haendler, Heus, Olsson, Carlsson, Roobol, Steineck, Wiklund (bib0030) 2014; 348 Melo, Sugimoto, O’Connell, Kato, Villanueva, Vidal, Qiu, Vitkin, Perelman, Melo, Lucci, Ivan, Calin, Kalluri (bib0105) 2014; 26 Kia, Paryan, Mortazavi, Biglari, Mohammadi-Yeganeh (bib0220) 2019; 120 Lamont, Tindall (bib0035) 2011; 25 Colombo, Raposo, Thery (bib0090) 2014; 30 Theodore, Rhim, Turner, Yates (bib0175) 2010; 20 Katakowski, Buller, Zheng, Lu, Rogers, Osobamiro, Shu, Jiang, Chopp (bib0095) 2013; 335 Shiao, Chu, Chung (bib0080) 2016; 380 Siegel (10.1016/j.biopha.2019.109109_bib0005) 2015; 65 Ratajczak (10.1016/j.biopha.2019.109109_bib0120) 2006; 20 Prasetyanti (10.1016/j.biopha.2019.109109_bib0155) 2017; 16 Wang (10.1016/j.biopha.2019.109109_bib0200) 2016; 14 Pullan (10.1016/j.biopha.2019.109109_bib0235) 2019; 16 Theodore (10.1016/j.biopha.2019.109109_bib0175) 2010; 20 Galletti (10.1016/j.biopha.2019.109109_bib0040) 2017; 57 Li (10.1016/j.biopha.2019.109109_bib0125) 2017; 44 Kato (10.1016/j.biopha.2019.109109_bib0185) 2015; 47 Li (10.1016/j.biopha.2019.109109_bib0215) 2016; 76 Hosseini-Beheshti (10.1016/j.biopha.2019.109109_bib0115) 2016; 7 Ren (10.1016/j.biopha.2019.109109_bib0020) 2013; 15 Petrylak (10.1016/j.biopha.2019.109109_bib0060) 2004; 351 Kavya (10.1016/j.biopha.2019.109109_bib0160) 2017; 433 Melo (10.1016/j.biopha.2019.109109_bib0105) 2014; 26 Liu (10.1016/j.biopha.2019.109109_bib0065) 2015; 75 Shiao (10.1016/j.biopha.2019.109109_bib0080) 2016; 380 Katakowski (10.1016/j.biopha.2019.109109_bib0095) 2013; 335 Uchiyama (10.1016/j.biopha.2019.109109_bib0145) 2017; 812 Anderson (10.1016/j.biopha.2019.109109_bib0085) 1969; 41 Yang (10.1016/j.biopha.2019.109109_bib0170) 2017; 21 Erdmann (10.1016/j.biopha.2019.109109_bib0140) 2016; 142 Dai (10.1016/j.biopha.2019.109109_bib0230) 2016; 7 Berthold (10.1016/j.biopha.2019.109109_bib0055) 2008; 26 Colombo (10.1016/j.biopha.2019.109109_bib0090) 2014; 30 Janowska-Wieczorek (10.1016/j.biopha.2019.109109_bib0110) 2001; 98 Kato (10.1016/j.biopha.2019.109109_bib0180) 2017; 62 Ratajczak (10.1016/j.biopha.2019.109109_bib0100) 2006; 20 Guo (10.1016/j.biopha.2019.109109_bib0190) 2016; 37 Srigley (10.1016/j.biopha.2019.109109_bib0010) 2005 Kia (10.1016/j.biopha.2019.109109_bib0220) 2019; 120 Li (10.1016/j.biopha.2019.109109_bib0210) 2013; 288 Rathkopf (10.1016/j.biopha.2019.109109_bib0045) 2017; 28 Cookson (10.1016/j.biopha.2019.109109_bib0050) 2013; 190 Sooriakumaran (10.1016/j.biopha.2019.109109_bib0030) 2014; 348 Lamont (10.1016/j.biopha.2019.109109_bib0035) 2011; 25 Chen (10.1016/j.biopha.2019.109109_bib0025) 2009; 10 Zhang (10.1016/j.biopha.2019.109109_bib0225) 2010; 39 Yuan (10.1016/j.biopha.2019.109109_bib0075) 2016; 35 Kaighn (10.1016/j.biopha.2019.109109_bib0165) 1979; 17 Zhang (10.1016/j.biopha.2019.109109_bib0015) 2016; 12 Fleige (10.1016/j.biopha.2019.109109_bib0150) 2006; 28 Wang (10.1016/j.biopha.2019.109109_bib0130) 2018; 49 Barrera-Ramirez (10.1016/j.biopha.2019.109109_bib0195) 2017; 13 Ahadi (10.1016/j.biopha.2019.109109_bib0205) 2016; 9 Xie (10.1016/j.biopha.2019.109109_bib0070) 2019; 145 Zhao (10.1016/j.biopha.2019.109109_bib0135) 2014; 35 |
| References_xml | – volume: 120 start-page: 5666 year: 2019 end-page: 5676 ident: bib0220 article-title: Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells publication-title: J. Cell. Biochem. – volume: 10 start-page: 981 year: 2009 end-page: 991 ident: bib0025 article-title: Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target, the Lancet publication-title: Oncology – volume: 30 start-page: 255 year: 2014 end-page: 289 ident: bib0090 article-title: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles publication-title: Annu. Rev. Cell Dev. Biol. – volume: 20 start-page: 1487 year: 2006 end-page: 1495 ident: bib0100 article-title: Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication publication-title: Leukemia – volume: 41 start-page: 59 year: 1969 end-page: 72 ident: bib0085 article-title: Vesicles associated with calcification in the matrix of epiphyseal cartilage publication-title: J. Cell Biol. – volume: 35 start-page: 9725 year: 2014 end-page: 9733 ident: bib0135 article-title: MiR-26a inhibits prostate cancer progression by repression of Wnt5a publication-title: Tumour Biol. – volume: 142 start-page: 2249 year: 2016 end-page: 2261 ident: bib0140 article-title: MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells publication-title: J. Cancer Res. Clin. Oncol. – volume: 13 start-page: 817 year: 2017 end-page: 825 ident: bib0195 article-title: Micro-RNA profiling of exosomes from marrow-derived mesenchymal stromal cells in patients with acute myeloid leukemia: implications in Leukemogenesis publication-title: Stem Cell Rev. – volume: 25 start-page: 897 year: 2011 end-page: 907 ident: bib0035 article-title: Minireview: alternative activation pathways for the androgen receptor in prostate cancer publication-title: Mol. Endocrinol. – volume: 380 start-page: 340 year: 2016 end-page: 348 ident: bib0080 article-title: Regulation of prostate cancer progression by the tumor microenvironment publication-title: Cancer Lett. – volume: 7 start-page: 21076 year: 2016 end-page: 21090 ident: bib0230 article-title: Human platelets repurposed as vehicles for in vivo imaging of myeloma xenotransplants publication-title: Oncotarget – volume: 9 start-page: 7 year: 2016 end-page: 9 ident: bib0205 article-title: A comparative analysis of lncRNAs in prostate cancer exosomes and their parental cell lines publication-title: Genom. Data – volume: 16 start-page: 1789 year: 2019 end-page: 1798 ident: bib0235 article-title: Exosomes as drug carriers for cancer therapy publication-title: Mol. Pharm. – volume: 57 start-page: 16 year: 2017 end-page: 27 ident: bib0040 article-title: Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer publication-title: Cancer Treat. Rev. – volume: 7 start-page: 14639 year: 2016 end-page: 14658 ident: bib0115 article-title: Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment publication-title: Oncotarget – volume: 145 start-page: 321 year: 2019 end-page: 328 ident: bib0070 article-title: Glioma stem cells reconstruct similar immunoinflammatory microenvironment in different transplant sites and induce malignant transformation of tumor microenvironment cells publication-title: J. Cancer Res. Clin. Oncol. – volume: 20 start-page: 847 year: 2006 end-page: 856 ident: bib0120 article-title: Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery publication-title: Leukemia – volume: 812 start-page: 138 year: 2017 end-page: 146 ident: bib0145 article-title: Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a publication-title: Eur. J. Pharmacol. – volume: 15 start-page: 350 year: 2013 end-page: 353 ident: bib0020 article-title: Prostate cancer research in China publication-title: Asian J. Androl. – volume: 335 start-page: 201 year: 2013 end-page: 204 ident: bib0095 article-title: Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth publication-title: Cancer Lett. – volume: 65 start-page: 5 year: 2015 end-page: 29 ident: bib0005 article-title: Cancer statistics, 2015 publication-title: CA Cancer J. Clin. – volume: 190 start-page: 429 year: 2013 end-page: 438 ident: bib0050 article-title: Castration-resistant prostate cancer: AUA guideline publication-title: J. Urol. – volume: 20 start-page: S1-96 year: 2010 end-page: 100 ident: bib0175 article-title: MiRNA 26a expression in a novel panel of African American prostate cancer cell lines publication-title: Ethn. Dis. – volume: 47 start-page: 710 year: 2015 end-page: 718 ident: bib0185 article-title: MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer publication-title: Int. J. Oncol. – volume: 26 start-page: 707 year: 2014 end-page: 721 ident: bib0105 article-title: Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis publication-title: Cancer Cell – volume: 351 start-page: 1513 year: 2004 end-page: 1520 ident: bib0060 article-title: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer publication-title: N. Engl. J. Med. – volume: 44 start-page: 1741 year: 2017 end-page: 1748 ident: bib0125 article-title: Exosomal microRNA MiR-1246 promotes cell proliferation, invasion and drug resistance by targeting CCNG2 in breast cancer publication-title: Cell. Physiol. Biochem. – start-page: 8 year: 2005 end-page: 19 ident: bib0010 article-title: Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives publication-title: Scand. J. Urol. Nephrol. Suppl. – volume: 21 start-page: 1918 year: 2017 end-page: 1923 ident: bib0170 article-title: Study on the influence of metformin on castration-resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCepsilon gene-mediated Notch1/Hes and androgen receptor signaling pathway publication-title: Eur. Rev. Med. Pharmacol. Sci. – volume: 12 start-page: 3397 year: 2016 end-page: 3402 ident: bib0015 article-title: Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2 publication-title: Oncol. Lett. – volume: 37 start-page: 12843 year: 2016 end-page: 12854 ident: bib0190 article-title: Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1 publication-title: Tumour Biol. – volume: 98 start-page: 3143 year: 2001 end-page: 3149 ident: bib0110 article-title: Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment publication-title: Blood – volume: 35 start-page: 2499 year: 2016 end-page: 2515 ident: bib0075 article-title: Role of the tumor microenvironment in tumor progression and the clinical applications (Review) publication-title: Oncol. Rep. – volume: 16 start-page: 41 year: 2017 ident: bib0155 article-title: Intra-tumor heterogeneity from a cancer stem cell perspective publication-title: Mol. Cancer – volume: 28 start-page: 2264 year: 2017 end-page: 2271 ident: bib0045 article-title: Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide publication-title: Ann. Oncol. – volume: 26 start-page: 242 year: 2008 end-page: 245 ident: bib0055 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study publication-title: J. Clin. Oncol. – volume: 14 start-page: 297 year: 2016 ident: bib0200 article-title: Exosomes in tumor microenvironment: novel transporters and biomarkers publication-title: J. Transl. Med. – volume: 75 start-page: 1001 year: 2015 end-page: 1008 ident: bib0065 article-title: Methylselenocysteine preventing castration-resistant progression of prostate cancer publication-title: Prostate – volume: 433 start-page: 13 year: 2017 end-page: 26 ident: bib0160 article-title: Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status publication-title: Mol. Cell. Biochem. – volume: 288 start-page: 23586 year: 2013 end-page: 23596 ident: bib0210 article-title: Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis publication-title: J. Biol. Chem. – volume: 348 start-page: g1502 year: 2014 ident: bib0030 article-title: Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes publication-title: BMJ – volume: 76 start-page: 1770 year: 2016 end-page: 1780 ident: bib0215 article-title: Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype publication-title: Cancer Res. – volume: 62 start-page: 123 year: 2017 end-page: 132 ident: bib0180 article-title: Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer publication-title: J. Hum. Genet. – volume: 49 start-page: 869 year: 2018 end-page: 883 ident: bib0130 article-title: Exosomal miR-27a derived from gastric cancer cells regulates the transformation of fibroblasts into cancer-associated fibroblasts publication-title: Cell. Physiol. Biochem. – volume: 39 start-page: 133 year: 2010 end-page: 144 ident: bib0225 article-title: Secreted monocytic miR-150 enhances targeted endothelial cell migration publication-title: Mol. Cell – volume: 28 start-page: 1601 year: 2006 end-page: 1613 ident: bib0150 article-title: Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR publication-title: Biotechnol. Lett. – volume: 17 start-page: 16 year: 1979 end-page: 23 ident: bib0165 article-title: Establishment and characterization of a human prostatic carcinoma cell line (PC-3) publication-title: Invest. Urol. – volume: 65 start-page: 5 issue: 1 year: 2015 ident: 10.1016/j.biopha.2019.109109_bib0005 article-title: Cancer statistics, 2015 publication-title: CA Cancer J. Clin. – volume: 10 start-page: 981 issue: 10 year: 2009 ident: 10.1016/j.biopha.2019.109109_bib0025 article-title: Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target, the Lancet publication-title: Oncology – volume: 25 start-page: 897 issue: 6 year: 2011 ident: 10.1016/j.biopha.2019.109109_bib0035 article-title: Minireview: alternative activation pathways for the androgen receptor in prostate cancer publication-title: Mol. Endocrinol. doi: 10.1210/me.2010-0469 – volume: 190 start-page: 429 issue: 2 year: 2013 ident: 10.1016/j.biopha.2019.109109_bib0050 article-title: Castration-resistant prostate cancer: AUA guideline publication-title: J. Urol. doi: 10.1016/j.juro.2013.05.005 – volume: 380 start-page: 340 issue: 1 year: 2016 ident: 10.1016/j.biopha.2019.109109_bib0080 article-title: Regulation of prostate cancer progression by the tumor microenvironment publication-title: Cancer Lett. doi: 10.1016/j.canlet.2015.12.022 – volume: 13 start-page: 817 issue: 6 year: 2017 ident: 10.1016/j.biopha.2019.109109_bib0195 article-title: Micro-RNA profiling of exosomes from marrow-derived mesenchymal stromal cells in patients with acute myeloid leukemia: implications in Leukemogenesis publication-title: Stem Cell Rev. doi: 10.1007/s12015-017-9762-0 – volume: 28 start-page: 2264 issue: 9 year: 2017 ident: 10.1016/j.biopha.2019.109109_bib0045 article-title: Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx283 – volume: 98 start-page: 3143 issue: 10 year: 2001 ident: 10.1016/j.biopha.2019.109109_bib0110 article-title: Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment publication-title: Blood doi: 10.1182/blood.V98.10.3143 – volume: 7 start-page: 21076 issue: 16 year: 2016 ident: 10.1016/j.biopha.2019.109109_bib0230 article-title: Human platelets repurposed as vehicles for in vivo imaging of myeloma xenotransplants publication-title: Oncotarget doi: 10.18632/oncotarget.8517 – volume: 7 start-page: 14639 issue: 12 year: 2016 ident: 10.1016/j.biopha.2019.109109_bib0115 article-title: Exosomes confer pro-survival signals to alter the phenotype of prostate cells in their surrounding environment publication-title: Oncotarget doi: 10.18632/oncotarget.7052 – volume: 16 start-page: 1789 issue: 5 year: 2019 ident: 10.1016/j.biopha.2019.109109_bib0235 article-title: Exosomes as drug carriers for cancer therapy publication-title: Mol. Pharm. doi: 10.1021/acs.molpharmaceut.9b00104 – volume: 20 start-page: S1-96 issue: 1 Suppl 1 year: 2010 ident: 10.1016/j.biopha.2019.109109_bib0175 article-title: MiRNA 26a expression in a novel panel of African American prostate cancer cell lines publication-title: Ethn. Dis. – volume: 26 start-page: 242 issue: 2 year: 2008 ident: 10.1016/j.biopha.2019.109109_bib0055 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2007.12.4008 – volume: 9 start-page: 7 year: 2016 ident: 10.1016/j.biopha.2019.109109_bib0205 article-title: A comparative analysis of lncRNAs in prostate cancer exosomes and their parental cell lines publication-title: Genom. Data doi: 10.1016/j.gdata.2016.05.010 – volume: 41 start-page: 59 issue: 1 year: 1969 ident: 10.1016/j.biopha.2019.109109_bib0085 article-title: Vesicles associated with calcification in the matrix of epiphyseal cartilage publication-title: J. Cell Biol. doi: 10.1083/jcb.41.1.59 – volume: 39 start-page: 133 issue: 1 year: 2010 ident: 10.1016/j.biopha.2019.109109_bib0225 article-title: Secreted monocytic miR-150 enhances targeted endothelial cell migration publication-title: Mol. Cell doi: 10.1016/j.molcel.2010.06.010 – volume: 120 start-page: 5666 issue: 4 year: 2019 ident: 10.1016/j.biopha.2019.109109_bib0220 article-title: Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells publication-title: J. Cell. Biochem. doi: 10.1002/jcb.27850 – volume: 16 start-page: 41 issue: 1 year: 2017 ident: 10.1016/j.biopha.2019.109109_bib0155 article-title: Intra-tumor heterogeneity from a cancer stem cell perspective publication-title: Mol. Cancer doi: 10.1186/s12943-017-0600-4 – volume: 57 start-page: 16 year: 2017 ident: 10.1016/j.biopha.2019.109109_bib0040 article-title: Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2017.04.008 – volume: 62 start-page: 123 issue: 1 year: 2017 ident: 10.1016/j.biopha.2019.109109_bib0180 article-title: Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer publication-title: J. Hum. Genet. doi: 10.1038/jhg.2016.68 – volume: 35 start-page: 2499 issue: 5 year: 2016 ident: 10.1016/j.biopha.2019.109109_bib0075 article-title: Role of the tumor microenvironment in tumor progression and the clinical applications (Review) publication-title: Oncol. Rep. doi: 10.3892/or.2016.4660 – volume: 49 start-page: 869 issue: 3 year: 2018 ident: 10.1016/j.biopha.2019.109109_bib0130 article-title: Exosomal miR-27a derived from gastric cancer cells regulates the transformation of fibroblasts into cancer-associated fibroblasts publication-title: Cell. Physiol. Biochem. doi: 10.1159/000493218 – volume: 351 start-page: 1513 issue: 15 year: 2004 ident: 10.1016/j.biopha.2019.109109_bib0060 article-title: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa041318 – volume: 14 start-page: 297 issue: 1 year: 2016 ident: 10.1016/j.biopha.2019.109109_bib0200 article-title: Exosomes in tumor microenvironment: novel transporters and biomarkers publication-title: J. Transl. Med. doi: 10.1186/s12967-016-1056-9 – volume: 17 start-page: 16 issue: 1 year: 1979 ident: 10.1016/j.biopha.2019.109109_bib0165 article-title: Establishment and characterization of a human prostatic carcinoma cell line (PC-3) publication-title: Invest. Urol. – volume: 12 start-page: 3397 issue: 5 year: 2016 ident: 10.1016/j.biopha.2019.109109_bib0015 article-title: Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2 publication-title: Oncol. Lett. doi: 10.3892/ol.2016.5070 – volume: 812 start-page: 138 year: 2017 ident: 10.1016/j.biopha.2019.109109_bib0145 article-title: Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2017.07.023 – volume: 76 start-page: 1770 issue: 7 year: 2016 ident: 10.1016/j.biopha.2019.109109_bib0215 article-title: Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-15-1625 – volume: 35 start-page: 9725 issue: 10 year: 2014 ident: 10.1016/j.biopha.2019.109109_bib0135 article-title: MiR-26a inhibits prostate cancer progression by repression of Wnt5a publication-title: Tumour Biol. doi: 10.1007/s13277-014-2206-4 – volume: 21 start-page: 1918 issue: 8 year: 2017 ident: 10.1016/j.biopha.2019.109109_bib0170 article-title: Study on the influence of metformin on castration-resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCepsilon gene-mediated Notch1/Hes and androgen receptor signaling pathway publication-title: Eur. Rev. Med. Pharmacol. Sci. – volume: 15 start-page: 350 issue: 3 year: 2013 ident: 10.1016/j.biopha.2019.109109_bib0020 article-title: Prostate cancer research in China publication-title: Asian J. Androl. doi: 10.1038/aja.2013.37 – volume: 26 start-page: 707 issue: 5 year: 2014 ident: 10.1016/j.biopha.2019.109109_bib0105 article-title: Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis publication-title: Cancer Cell doi: 10.1016/j.ccell.2014.09.005 – volume: 47 start-page: 710 issue: 2 year: 2015 ident: 10.1016/j.biopha.2019.109109_bib0185 article-title: MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer publication-title: Int. J. Oncol. doi: 10.3892/ijo.2015.3043 – volume: 28 start-page: 1601 issue: 19 year: 2006 ident: 10.1016/j.biopha.2019.109109_bib0150 article-title: Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR publication-title: Biotechnol. Lett. doi: 10.1007/s10529-006-9127-2 – volume: 348 start-page: g1502 year: 2014 ident: 10.1016/j.biopha.2019.109109_bib0030 article-title: Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes publication-title: BMJ doi: 10.1136/bmj.g1502 – volume: 20 start-page: 847 issue: 5 year: 2006 ident: 10.1016/j.biopha.2019.109109_bib0120 article-title: Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery publication-title: Leukemia doi: 10.1038/sj.leu.2404132 – volume: 145 start-page: 321 issue: 2 year: 2019 ident: 10.1016/j.biopha.2019.109109_bib0070 article-title: Glioma stem cells reconstruct similar immunoinflammatory microenvironment in different transplant sites and induce malignant transformation of tumor microenvironment cells publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-018-2786-2 – volume: 30 start-page: 255 year: 2014 ident: 10.1016/j.biopha.2019.109109_bib0090 article-title: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles publication-title: Annu. Rev. Cell Dev. Biol. doi: 10.1146/annurev-cellbio-101512-122326 – volume: 433 start-page: 13 issue: 1-2 year: 2017 ident: 10.1016/j.biopha.2019.109109_bib0160 article-title: Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-017-3012-2 – volume: 44 start-page: 1741 issue: 5 year: 2017 ident: 10.1016/j.biopha.2019.109109_bib0125 article-title: Exosomal microRNA MiR-1246 promotes cell proliferation, invasion and drug resistance by targeting CCNG2 in breast cancer publication-title: Cell. Physiol. Biochem. doi: 10.1159/000485780 – volume: 37 start-page: 12843 issue: 9 year: 2016 ident: 10.1016/j.biopha.2019.109109_bib0190 article-title: Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1 publication-title: Tumour Biol. doi: 10.1007/s13277-016-5158-z – volume: 20 start-page: 1487 issue: 9 year: 2006 ident: 10.1016/j.biopha.2019.109109_bib0100 article-title: Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication publication-title: Leukemia doi: 10.1038/sj.leu.2404296 – start-page: 8 issue: 216 year: 2005 ident: 10.1016/j.biopha.2019.109109_bib0010 article-title: Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives publication-title: Scand. J. Urol. Nephrol. Suppl. doi: 10.1080/03008880510030914 – volume: 288 start-page: 23586 issue: 32 year: 2013 ident: 10.1016/j.biopha.2019.109109_bib0210 article-title: Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis publication-title: J. Biol. Chem. doi: 10.1074/jbc.M113.489302 – volume: 335 start-page: 201 issue: 1 year: 2013 ident: 10.1016/j.biopha.2019.109109_bib0095 article-title: Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth publication-title: Cancer Lett. doi: 10.1016/j.canlet.2013.02.019 – volume: 75 start-page: 1001 issue: 9 year: 2015 ident: 10.1016/j.biopha.2019.109109_bib0065 article-title: Methylselenocysteine preventing castration-resistant progression of prostate cancer publication-title: Prostate doi: 10.1002/pros.22987 – volume: 142 start-page: 2249 issue: 11 year: 2016 ident: 10.1016/j.biopha.2019.109109_bib0140 article-title: MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-016-2222-4 |
| SSID | ssj0005638 |
| Score | 2.3763802 |
| Snippet | Prostate carcinoma may develop into metastatic castration-resistant prostate carcinoma (mCRPC) after endocrine therapy. Exosomal microRNAs play an important... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 109109 |
| SubjectTerms | Animals Castration-resistant prostate carcinoma Cell Line, Tumor Cell Movement Cell Proliferation Epithelial-Mesenchymal Transition - genetics Exosomes Exosomes - metabolism Exosomes - ultrastructure Gene Expression Regulation, Neoplastic Humans Male Mice Mice, Inbred BALB C Mice, Nude microRNA-26a MicroRNAs - genetics MicroRNAs - metabolism Neoplasm Invasiveness Neoplasm Metastasis Prostate carcinoma Prostatic Neoplasms - genetics Prostatic Neoplasms - pathology |
| Title | Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0753332219318177 https://dx.doi.org/10.1016/j.biopha.2019.109109 https://www.ncbi.nlm.nih.gov/pubmed/31229922 https://www.proquest.com/docview/2246248238 |
| Volume | 117 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemISFeEIyvMpiMhPY00yR2bOexmpgKqFUFm7Q3y44dKFqTakkn9sLfzl0-OhCgIR5j-ZzEd_b9nNz9jpDXWZZ76SLPlLMREyFophMlmRXCAkJ1XkvMRp7N5fRMvD9Pz3fI8ZALg2GV_d7f7entbt23jPvZHK-Xy_EncHacgz0CBAE3pTCjHNnrwKbffP8pzEO21ayxM8PeQ_pcG-PllhWSMoETzJBXqQ1L_LN7-hv8bN3QyQNyv8ePdNI94kOyE8o9cnfW_yHfI4eLjov6-oie3qRW1Uf0kC5uWKqvH5HNAvM9AGnSHMsJldXKUvyKzzzY5FXwNHyrami8oDOM2fs4n7BEWrqqPBb8CjUF5EhXobEwSL2sqS09bTar6pJ-hpN984VWBV3_dovH5Ozk7enxlPU1GFguZNyA4tIQW3DsIudKycI5GbTXAk5tKooLHaXacq2LALBAOZV6qyJV8AJQQJYXoeBPyG5ZleEZoVwFLqVNncssjAYmLG0sXaqc8LmUfkT4MPUm7wnKsU7GhRki0b6aTmEGFWY6hY0I20qtO4KOW_qng1bNkHwK26UBD3KLnNrK_WKg_yD5ajAeA2sXVWnLUG1qg2R-idCAmkbkaWdV23fgcZIgZ_Dz_77vPrmHV11A3Auy21xuwktAUI07aJfIAbkzefdhOv8BAd0biA |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NTgJeEIyv8mkktKdZTeLEdh6rialja1VBJ-3NsmMHitakWlLE_nvO-WiFAA3xmvjsxHf2_Zzc_Q7gfZpmlpvAUmF0QGPnJJWR4FTHsUaEaqzkPht5OuOTi_jjZXK5B8d9LowPq-z2_nZPb3br7sqom83RerkcfUZnxxjaI0IQdFNC3IF9z04VD2B_fHo2me0iPXhT0Nq3p16gz6BrwrzMsvS8TOgHU0-t1EQm_tlD_Q2BNp7o5CE86CAkGbdP-Qj2XHEAd6fdT_IDOJy3dNQ3R2Sxy66qjsghme-Iqm8ew2buUz4QbJLMVxQqypUm_kM-tWiW350l7kdZ4cUrMvVhe59mYxpxTVal9TW_XEUQPJKVqzV2Ui0rogtL6s2qvCZf8HBffyVlTta_DfEELk4-LI4ntCvDQLOYhzXqLnGhRt8eZ0wInhvDnbQyxoObCMJcBonUTMrcITIQRiRWi0DkLEcgkGa5y9lTGBRl4Z4DYcIxznViTKqxN7RirkNuEmFim3Fuh8D6qVdZx1HuS2VcqT4Y7ZtqFaa8wlSrsCHQrdS65ei4pX3Sa1X1-ae4Yyp0IrfIia3cLzb6D5LveuNRuHy9KnXhyk2lPJ9fFEsETkN41lrV9h1YGEWeNvjFf4_7Fu5NFtNzdX46O3sJ9_2dNj7uFQzq6417jYCqNm-6BfMTpYseOQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prostate+carcinoma+cell-derived+exosomal+MicroRNA-26a+modulates+the+metastasis+and+tumor+growth+of+prostate+carcinoma&rft.jtitle=Biomedicine+%26+pharmacotherapy&rft.au=Wang%2C+Xiaobin&rft.au=Wang%2C+Xi&rft.au=Zhu%2C+Zhiyi&rft.au=Li%2C+Wensheng&rft.date=2019-09-01&rft.issn=0753-3322&rft.volume=117&rft.spage=109109&rft_id=info:doi/10.1016%2Fj.biopha.2019.109109&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_biopha_2019_109109 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0753-3322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0753-3322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0753-3322&client=summon |